Efficacy, Safety, and Pharmacokinetics of Intravenous Ibuprofen in Adult Febrile Patients
Primary Purpose
Fever
Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Ibuprofen
Ibuprofen
Ibuprofen
Normal Saline
Sponsored by
About this trial
This is an interventional treatment trial for Fever
Eligibility Criteria
Inclusion Criteria:
- Be hospitalized
- Have new (not chronic, within last 7 days) onset of fever, documented by temperature greater than or equal to 101.0ºF (38.3ºC)
- Have adequate intravenous access
- Have the ability to understand the requirements of the study, be willing to provide written informed consent (as evidenced by signature on an informed consent document approved by an Institutional Review Board), and agree to abide by the study restrictions and to return for the required assessments
Exclusion Criteria:
- Be less than 18 years of age
- Have received antipyretic drug therapy (e.g., aspirin, other NSAIDs, or acetaminophen) within 4 hours before dosing
- Have any history of allergy or hypersensitivity to any component of IVIb, NSAIDs (including aspirin), or COX-2 inhibitors
- Be pregnant or nursing
- Have a history of severe head trauma that required current hospitalization, intracranial surgery, or stroke within the previous 30 days, or any history of intracerebral arteriovenous malformation, cerebral aneurysm, or central nervous system mass lesions
- Weigh less than 40 kg
- Have a history of congenital bleeding diatheses (e.g., hemophilia) or any active clinically significant bleeding, or have underlying platelet dysfunction, including (but not limited to) idiopathic thrombocytopenic purpura, disseminated intravascular coagulation, or congenital platelet dysfunction
- Have gastrointestinal bleeding that has required medical intervention within the previous 6 weeks (unless definitive surgery has been performed)
- Have a platelet count less than 30,000/mm3
- Be receiving full dose anticoagulation therapy
- Have fever secondary to blood or drug reaction
- Have an expected life span of less than 14 days because of imminent withdrawal of life support or severity of illness
- Be receiving treatment with corticosteroids (Patients who are expected to receive corticosteroids during the Treatment Period or through Hour 120 of the Post-treatment Period are not eligible.)
- Have neurogenic fever
- Be on dialysis, have oliguria or creatinine greater than 3.0 mg/dL, or be receiving nephrotoxic drugs
- Have had major surgery within the past 12 hours, unless adequate hemostasis has been achieved
- Have received another investigational drug within the past 30 days
- Become afebrile (temperature below 101.0ºF [38.3ºC]) before dosing and not redevelop fever entry criteria during this hospitalization
- Be otherwise unsuitable for the study, in the opinion of the Investigator
Sites / Locations
- Orlando Regional Medical Center
- Barnes Jewish Hospital
- Moses H. Cone Memorial Hospital
- Wake Forest University Health Sciences
- Methodist Healthcare - University Hospital
- Vanderbilt University Medical Center
- Skyline Medical Center
- Ben Taub General Hospital
- Newcastle Mater Misericordiae Hospital
- Flinders Medical Centre
- Mahidol University Siriraj Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Ibuprofen
Saline
Arm Description
Normal Saline
Outcomes
Primary Outcome Measures
Percent of patients with fever reduction to less than 101.0 degree fahrenheit following a single dose of intravenous ibuprofen.
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01131000
Brief Title
Efficacy, Safety, and Pharmacokinetics of Intravenous Ibuprofen in Adult Febrile Patients
Official Title
A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Trial To Evaluate The Efficacy, Safety, and Pharmacokinetics of Ibuprofen Injection in Adult Febrile Patients
Study Type
Interventional
2. Study Status
Record Verification Date
May 2010
Overall Recruitment Status
Completed
Study Start Date
June 2002 (undefined)
Primary Completion Date
August 2005 (Actual)
Study Completion Date
August 2005 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Cumberland Pharmaceuticals
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The primary objective of this study is to evaluate the efficacy of intravenous ibuprofen on reducing fever at 4 hours.
Detailed Description
The primary objective of this study is to evaluate the efficacy of a single 400 mg dose of intravenous ibuprofen on reducing fever greater than or equal to 101.0ºF (38.3ºC), as compared with the efficacy of parallel placebo treatment.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fever
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
123 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Ibuprofen
Arm Type
Experimental
Arm Title
Saline
Arm Type
Placebo Comparator
Arm Description
Normal Saline
Intervention Type
Drug
Intervention Name(s)
Ibuprofen
Intervention Description
Intravenous ibuprofen, 100 mg, Single-dose
Intervention Type
Drug
Intervention Name(s)
Ibuprofen
Intervention Description
Intravenous ibuprofen, 200mg, single dose
Intervention Type
Drug
Intervention Name(s)
Ibuprofen
Intervention Description
Intravenous ibuprofen, 400 mg, Single-dose
Intervention Type
Other
Intervention Name(s)
Normal Saline
Other Intervention Name(s)
0.9 % NaCL; 0.9 % Sodium Chloride
Intervention Description
Normal Saline, 100 ml, Single-dose
Primary Outcome Measure Information:
Title
Percent of patients with fever reduction to less than 101.0 degree fahrenheit following a single dose of intravenous ibuprofen.
Time Frame
4 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Be hospitalized
Have new (not chronic, within last 7 days) onset of fever, documented by temperature greater than or equal to 101.0ºF (38.3ºC)
Have adequate intravenous access
Have the ability to understand the requirements of the study, be willing to provide written informed consent (as evidenced by signature on an informed consent document approved by an Institutional Review Board), and agree to abide by the study restrictions and to return for the required assessments
Exclusion Criteria:
Be less than 18 years of age
Have received antipyretic drug therapy (e.g., aspirin, other NSAIDs, or acetaminophen) within 4 hours before dosing
Have any history of allergy or hypersensitivity to any component of IVIb, NSAIDs (including aspirin), or COX-2 inhibitors
Be pregnant or nursing
Have a history of severe head trauma that required current hospitalization, intracranial surgery, or stroke within the previous 30 days, or any history of intracerebral arteriovenous malformation, cerebral aneurysm, or central nervous system mass lesions
Weigh less than 40 kg
Have a history of congenital bleeding diatheses (e.g., hemophilia) or any active clinically significant bleeding, or have underlying platelet dysfunction, including (but not limited to) idiopathic thrombocytopenic purpura, disseminated intravascular coagulation, or congenital platelet dysfunction
Have gastrointestinal bleeding that has required medical intervention within the previous 6 weeks (unless definitive surgery has been performed)
Have a platelet count less than 30,000/mm3
Be receiving full dose anticoagulation therapy
Have fever secondary to blood or drug reaction
Have an expected life span of less than 14 days because of imminent withdrawal of life support or severity of illness
Be receiving treatment with corticosteroids (Patients who are expected to receive corticosteroids during the Treatment Period or through Hour 120 of the Post-treatment Period are not eligible.)
Have neurogenic fever
Be on dialysis, have oliguria or creatinine greater than 3.0 mg/dL, or be receiving nephrotoxic drugs
Have had major surgery within the past 12 hours, unless adequate hemostasis has been achieved
Have received another investigational drug within the past 30 days
Become afebrile (temperature below 101.0ºF [38.3ºC]) before dosing and not redevelop fever entry criteria during this hospitalization
Be otherwise unsuitable for the study, in the opinion of the Investigator
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gordon Bernard, M.D.
Organizational Affiliation
Cumberland Pharmaceuticals, Inc.
Official's Role
Study Chair
Facility Information:
Facility Name
Orlando Regional Medical Center
City
Orlando
State/Province
Florida
ZIP/Postal Code
32806
Country
United States
Facility Name
Barnes Jewish Hospital
City
St. Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Facility Name
Moses H. Cone Memorial Hospital
City
Greensboro
State/Province
North Carolina
ZIP/Postal Code
27401
Country
United States
Facility Name
Wake Forest University Health Sciences
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27157
Country
United States
Facility Name
Methodist Healthcare - University Hospital
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38104
Country
United States
Facility Name
Vanderbilt University Medical Center
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37203
Country
United States
Facility Name
Skyline Medical Center
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37207
Country
United States
Facility Name
Ben Taub General Hospital
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
Newcastle Mater Misericordiae Hospital
City
New Lambton
State/Province
New South Wales
ZIP/Postal Code
2305
Country
Australia
Facility Name
Flinders Medical Centre
City
Adelaide
State/Province
South Australia
Country
Australia
Facility Name
Mahidol University Siriraj Hospital
City
Bangkok
ZIP/Postal Code
10700
Country
Thailand
12. IPD Sharing Statement
Citations:
PubMed Identifier
20591173
Citation
Morris PE, Promes JT, Guntupalli KK, Wright PE, Arons MM. A multi-center, randomized, double-blind, parallel, placebo-controlled trial to evaluate the efficacy, safety, and pharmacokinetics of intravenous ibuprofen for the treatment of fever in critically ill and non-critically ill adults. Crit Care. 2010;14(3):R125. doi: 10.1186/cc9089. Epub 2010 Jun 30.
Results Reference
derived
Learn more about this trial
Efficacy, Safety, and Pharmacokinetics of Intravenous Ibuprofen in Adult Febrile Patients
We'll reach out to this number within 24 hrs